What are the possible side effects of RADICAVA?

RADICAVA (EDARAVONE) Injection is a medication used to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. As with any medication, RADICAVA may cause side effects in some people. It is important to understand the possible side effects of RADICAVA and to talk to your doctor if you experience any of these symptoms.



Common side effects of RADICAVA may include:


Bruising or swelling at the injection site

Gait disturbance or difficulty walking

Headache

Skin rash or itching

Fever

These side effects are typically mild to moderate in severity and may go away on their own without treatment. However, if these side effects persist or worsen, it is important to talk to your doctor.


Less common but more serious side effects of RADICAVA may include:


Allergic reaction: In rare cases, RADICAVA may cause an allergic reaction, which can be life-threatening. Signs of an allergic reaction may include difficulty breathing, hives, or swelling of the face, lips, tongue, or throat. If you experience any of these symptoms after receiving RADICAVA, seek emergency medical attention right away.


Worsening of ALS symptoms: RADICAVA may cause worsening of ALS symptoms, such as muscle weakness, breathing problems, or difficulty speaking. If you experience any of these symptoms after receiving RADICAVA, talk to your doctor.


It is important to note that the above lists of side effects are not exhaustive, and other side effects may occur. Talk to your doctor if you have any concerns or if you experience any new or worsening symptoms while taking RADICAVA.


To minimize the risk of side effects, it is important to follow your doctor's dosage instructions and receive RADICAVA only under medical supervision. Your doctor may monitor your liver function and blood cell counts while you are receiving RADICAVA, as the medication may affect these parameters.


In summary, RADICAVA (EDARAVONE) Injection is a medication used to treat ALS, and it may cause side effects in some people. Common side effects of RADICAVA may include bruising or swelling at the injection site, gait disturbance, headache, skin rash, and fever. Less common but more serious side effects may include allergic reactions or worsening of ALS symptoms. Talk to your doctor if you have any concerns or if you experience any new or worsening symptoms while taking RADICAVA.




 

Location: FLOOR, S, 9, Green Park Ext Rd, Block J, Green Park Extension, Green Park, New Delhi, Delhi 110016, India

Comments

Post a Comment

Popular posts from this blog

Treatment for Acute Myeloid Leukemia: IDHIFA (Enasidenib)

Image
  In the world of oncology, breakthroughs in targeted therapies have opened new avenues for the treatment of various types of cancer. One such remarkable advancement is the introduction of IDHIFA (Enasidenib), a medication that has shown great promise in the fight against acute myeloidleukemia (AML) . Understanding IDHIFA and AML:  IDHIFA, known by its generic name Enasidenib, is an oral medication that targets a specific mutation known as isocitrate dehydrogenase 2 (IDH2). Mutations in the IDH2 gene are found in approximately 12-20% of AML patients. These mutations lead to the production of an abnormal form of the IDH2 enzyme, which plays a significant role in the development and progression of AML. Approved Indication: IDHIFA is specifically indicated for the treatment of adult patients with relapsed or refractory AML harboring an IDH2 mutation. It is not intended for use in patients with other types of leukemia or those without the IDH2 mutation. Accessing IDHIFA: Obtaining IDHIFA
Read more

What Patients Should Know about Early Access Programs- AlleviareIndia

Image
  Introduction: In the world of medical research and development, new treatments, drugs, and therapies are constantly being developed to address various health conditions. However, the journey from initial development to final approval by regulatory authorities can be a lengthy process, leaving many patients eagerly awaiting access to potentially life-saving treatments. This is where Early Access Programs (EAPs) come into play. In this article, we will explore what patients should consider when participating in an Early Access Program. Understand the Purpose and Eligibility Criteria: Before considering participation in an Early Access Program, it's important to understand its purpose. EAPs are designed to provide access to investigational treatments for patients who have exhausted all other available options and have a serious or life-threatening condition. Familiarize yourself with the eligibility criteria to determine if you meet the necessary requirements. Discuss with
Read more

Abatacept (Orencia)

Image
Abatacept (Orencia) is often prescribed after failure of an anti-rheumatic agent (DMARD), such as methotrexate. But it can be used as first-line therapy. Ebetasip is used to reduce inflammatory symptoms such as swelling, pain, and stiffness. In the long term, it is expected to prevent joint deformity, therefore helping to maintain range of motion. It is often used in patients with moderate to severe rheumatoid arthritis who have not responded to one or more DMARDs, such as methotrexate, or other biologic drugs. DMARDs are usually tried first. Abatacept may be used alone or in combination with DMARDs, which makes it more potent, but not with other biologic drugs (such as TNF inhibitors). Its use in other diseases is still being studied. Unlike some other biologic drugs, abetacept does not block anti-inflammatory proteins such as TNF-alpha antagonists. Abatacept attaches to the surface of inflammatory cells and blocks communication between these cells. By blocking this communicatio
Read more